First Drug To Show Benefit In Scleroderma

11 June 1997

Connetics has reported positive Phase II data which suggest that ConXn(recombinant human relaxin H2) may be the first effective treatment for scleroderma, a currently untreatable and life-threatening connective tissue disorder.

The 64-patient study found that ConXn was associated with a significant improvement in skin scores, the primary endpoint, and positive trends were seen in other measures. The data will be presented at the American Academy of Rheumatology meeting in November.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight